An update on the QuANTUM-First trial: quizartinib plus chemotherapy in FLT3-mutated AML скачать в хорошем качестве

An update on the QuANTUM-First trial: quizartinib plus chemotherapy in FLT3-mutated AML

Harry Erba, MD, PhD, Duke University, Durham, NC, discusses the QuANTUM-First trial (NCT02668653), which evaluated quizartinib plus chemotherapy in newly diagnosed patients with FLT3-mutated acute myeloid leukemia (AML). The trial met its primary endpoint, showing higher overall survival (OS) in the experimental arm compared to placebo, with a hazard ratio of 0.78. Quizartinib treatment also improved relapse-free survival and the duration of remissions, though it was associated with increased toxicities. The benefits were most notable in patients under 60 years old. Quizartinib maintenance before allogeneic stem cell transplantation (alloSCT) did not improve survival compared to placebo, but it did offer a survival benefit for patients who did not undergo alloSCT. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.